Corps Capital Advisors’s AbbVie ABBV Stock Holding History

Corps Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.42M	Sell	5,648 -44	-0.8%	-$9.47K	1.15%	26
2026 Q1	$1.24M	Sell	5,692 -10	-0.2%	-$2.22K	1.07%	26
2025 Q4	$1.3M	Buy	5,702 +1,360	+31%	+$310K	1.35%	20
2025 Q3	$1.01M	Hold	4,342	–	–	1.52%	20
2025 Q2	$806K	Sell	4,342 -4,803	-53%	-$893K	1.3%	24
2025 Q1	$1.92M	Hold	9,145	–	–	2.02%	12
2024 Q4	$1.63M	Buy	+9,145	New	+$1.68M	1.65%	19

Other funds holding ABBV

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

ECSS

Eurizon Capital SGR SpA Milan $37.3B AUM

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Corps Capital Advisors's ABBV Position: Q2 2026 in Review

Corps Capital Advisors reduced its AbbVie (ABBV) stake by 0.77% in Q2 2026, selling an estimated $9.47K and leaving 5,648 shares worth $1.42M. The position accounts for 1.15% of the portfolio, ranked #26.

Corps Capital Advisors first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.92M in Q1 2025. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Corps Capital Advisors held 5,648 shares of AbbVie worth $1.42M as of Q2 2026.
Corps Capital Advisors sold 44 AbbVie shares in Q2 2026, an estimated $9.47K.
AbbVie made up 1.15% of Corps Capital Advisors's portfolio in Q2 2026, its #26 holding.
Corps Capital Advisors first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
Corps Capital Advisors's AbbVie position peaked at $1.92M in Q1 2025.
2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Corps Capital Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.